莱博雷生通过时间依赖性抑制CYP3A4升高氯氮平暴露:一例药物相互作用报告
本文报告一例35岁男性难治性精神分裂症非吸烟患者,在加用莱博雷生治疗失眠后,氯氮平及其活性代谢物N-去甲基氯氮平的稳态谷浓度显著升高,出现过度镇静,停用莱博雷生后浓度恢复正常。体外实验显示莱博雷生经NADPH预孵育后对CYP3A4介导的氯氮平代谢产生显著时间依赖性抑制,提示两者合用可能增加氯氮平暴露及相关不良事件风险。
要点
- 氯氮平与莱博雷生合用可致氯氮平及N-去甲基氯氮平稳态谷浓度显著升高。
- 合用期间出现过度镇静、嗜睡和疲劳,停用莱博雷生后氯氮平浓度恢复正常。
- 莱博雷生经NADPH预孵育后对CYP3A4呈时间依赖性抑制,提示机制为CYP3A4抑制。
核心结论
- 氯氮平与莱博雷生合用可能因莱博雷生时间依赖性抑制CYP3A4而增加氯氮平暴露,并带来氯氮平相关不良事件风险。
研究设计与样本
- 病例报告:一例35岁男性非吸烟难治性精神分裂症患者,接受氯氮平治疗期间加用口服莱博雷生治疗失眠。
- 体外实验:测定CYP1A2和CYP3A4介导的氯氮平代谢产物N-去甲基氯氮平和氯氮平N-氧化物的生成。
主要发现
- 患者加用莱博雷生后氯氮平及N-去甲基氯氮平的稳态谷浓度显著升高,并出现过度镇静、嗜睡和疲劳。
- 停用莱博雷生后升高的氯氮平浓度恢复正常范围。
- 体外实验中莱博雷生对CYP1A2和CYP3A4介导的氯氮平代谢仅有弱抑制作用。
- 莱博雷生在NADPH存在下与CYP3A4预孵育后,对氯氮平代谢的抑制作用显著增强,形成氯氮平N-氧化物和N-去甲基氯氮平的IC50分别为2.8 μM和4.1 μM。
关键数值与推荐
- 莱博雷生经NADPH预孵育后对CYP3A4介导的氯氮平N-氧化物生成的IC50为2.8 μM。
- 莱博雷生经NADPH预孵育后对CYP3A4介导的N-去甲基氯氮平生成的IC50为4.1 μM。
临床怎么用
- 临床在为氯氮平治疗患者处方莱博雷生时应警惕潜在的药物相互作用,监测氯氮平血药浓度及镇静等不良反应。
局限性
- 证据主要来自单例病例报告和体外实验,尚需更多临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clozapine (CLZ) is extensively used for treatment-resistant schizophrenia (TRS) with caution to avoid serious adverse events such as agranulocytosis and drug-drug interactions (DDIs). In the current report, we present a case of a 35-year-old male non-smoking TRS patient whose steady-state plasma trough concentrations (Ctrough ) of CLZ and its active metabolite, N-desmethylclozapine (NDMC), were significantly increased after initiating oral administration of lemborexant (LEM), a dual orexin receptor antagonist, for the treatment of insomnia. The patient experienced oversedation with sleepiness and fatigue while maintaining high levels of Ctrough of CLZ. The increased concentrations of CLZ returned to normal ranges after the discontinuation of LEM dosing, implying a pharmacokinetic DDI between CLZ and LEM. To gain insight into possible mechanisms, we performed in vitro assays of CYP1A2- and CYP3A4-mediated CLZ metabolism by measuring the formations of NDMC and clozapine N-oxide (CNO). In accordance with previous studies, the incubation of CLZ with each enzyme resulted in the production of both metabolites. LEM had only a weak inhibitory effect on CYP1A2- and CYP3A4-mediated CLZ metabolism. However, the preincubation of LEM with CYP3A4 in the presence of NADPH showed a significant enhancement of inhibitory effects on CLZ metabolism with IC50 values for the formations of CNO and NDMC of 2.8 μM and 4.1 μM, respectively, suggesting that LEM exerts as a potent time-dependent inhibitor for CYP3A4. Taken together, the results of the current study indicate that co-medication of CLZ with LEM may lead to increase in exposure to CLZ and risks of CLZ-related adverse events.
引用
- Watanabe K, Misaka S, Kanno-Nozaki K, et al. Effect of lemborexant on pharmacokinetics of clozapine: A potential drug-drug interaction mediated by time-dependent inhibition of CYP3A4. Br J Clin Pharmacol. 2023. PMID: 37596710. doi:10.1111/bcp.15889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。